Schering AG: Board of Executive Directors allocates responsibilities
Berlin, Germany, December 21, 2000; Following the announcement of Dr. Hubertus
Erlen as Chairman-elect and of Mr. Lutz Lingnau as a new member of the Board of
Executive Directors of Schering AG, Berlin (NYSE: SHR), the Board of Executive
Directors announced its allocation of Board's responsibilities. These changes
have been presented to the Supervisory Board and the employees and will be
effective from April 26, 2001.
The Board's new responsibilities focus on Schering's strategy and the horizontal
integration of its business processes. Furthermore, the corporate role of
Schering's US-organization will be strengthened.
The reponsibilities are as follows:
- Dr. Hubertus Erlen as Chairman will focus on strategy and corporate
development, corporate communication, audit, and human resources.
- Prof. Dr. Klaus Pohle, Vice Chairman, will continue to be responsible for
equity participations, finance, administration and information technology as
well as for Japan, Asia and Australia.
- Dr. Ulrich Koestlin will be responsible for the business processes marketing,
sales and supply chain and for Europe and Africa.
- Mr. Lutz Lingnau - located in the USA - will take responsibility for the
business areas therapeutics and dermatology as well as for North America.
- Prof. Dr. Guenter Stock will be responsible for the business areas fertility
control/hormone therapy and diagnostics/radiopharmaceuticals, for research and
product development as well as for Latin America.
To strengthen the corporate role of the US-organization, all members of the
Board of Schering AG will also be members of the Board of Schering Berlin Inc.,
the US management holding company. Dr. Erlen will be Chairman. In addition,
Mr. Lingnau and Prof. Stock have been elected President and Chief Executive
Officer and Chief Scientific Officer respectively of Schering Berlin Inc.
Dr. Dale Stringfellow has been appointed President and Chief Executive Officer
of the US-affiliate, Berlex Laboratories Inc. Dr. Stringfellow, who is currently
President of the Schering-research and development center Berlex Biosciences in
Richmond, California, will report to Mr. Lingnau.
Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: fertility control and hormone therapy,
diagnostics and radiopharmaceuticals, dermatology as well as therapeutics for
disabling diseases, e.g. multiple sclerosis, leukemia and solid tumors. As a
global player with innovative products Schering AG aims for leading positions
in specialized markets worldwide. With in-house R&D and supported by an
excellent global network with external partners, Schering AG is securing a
promising product pipeline. Using new ideas, Schering AG aims to make a
recognized contribution to medical progress and strives to improve the quality
of life.
An electronic version of this news release - as well as additional information
about Schering AG - is available at www.schering.de
Berlin, Germany, December 21, 2000
Schering AG
Corporate Communication
For further information please contact:
Dr. Friedrich von Heyl Peter Vogt
Business and Financial Communication Investor Relations
Phone: +49 - 30 - 468 152 96 Phone: +49 - 30 - 468 124 31
Fax: +49 - 30 - 468 166 46 Fax: +49 - 30 - 468 166 46
[email protected] [email protected]
